CSL Behring GmbH
Records under this name other than the patents CSL Behring GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 60 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,939,288 | Method for differentiating between factor XIII deficiency states and fibrinogen deficiency states by means of thrombelastographic techniques Formerly held In force (reinstated) · From the USPTO record | In force (reinstated) | From the USPTO record | |
| US 8,632,773 | Antibody Composition with Altered Fab Sialylation Formerly held In force · High confidence | In force | High confidence | |
| US 8,999,920 | Reconstituted high density lipoprotein formulation and production method thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,125,943 | Reconstituted HDL formulation Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,925,236 | Reconstituted HDL formulation Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,603,355 | Reconstructed HDL formulation Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,957,731 | Reconstituted HDL formulation Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,518,127 | Inhibitory Anti-Factor XII/Xiia Monoclonal Antibodies and Their Uses Formerly held In force · High confidence | In force | High confidence | |
| US 11,464,828 | Reconstituted HDL formulation Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,286,047 | Treatment and Prevention of Remote Ischemia-Reperfusion Injury Formerly held In force · Medium confidence | In force | Medium confidence |